Phenotypic variability in childhood TB: Implications for diagnostic endpoints in tuberculosis vaccine trials

被引:14
|
作者
Mulenga, Humphrey [2 ]
Moyo, Sizulu [2 ]
Workman, Lesley [2 ]
Hawkridge, Tony
Verver, Suzanne [3 ]
Tameris, Michele [2 ]
Geldenhuys, Hennie [2 ]
Hanekom, Willem [2 ]
Mahomed, Hassan [2 ]
Hussey, Gregory [2 ]
Hatherill, Mark [1 ,2 ]
机构
[1] Univ Cape Town, SATVI, IIDMM, Fac Hlth Sci, ZA-7925 Observatory, South Africa
[2] Univ Cape Town, Sch Child & Adolescent Hlth, ZA-7925 Observatory, South Africa
[3] KNCV TB Fdn, The Hague, Netherlands
关键词
Tuberculosis; Child; Diagnosis; Endpoint; Case definition; PRE-CHEMOTHERAPY ERA; PULMONARY TUBERCULOSIS; BCG VACCINATION; YOUNG-CHILDREN; GASTRIC LAVAGE; INDUCED SPUTUM; INFANTS;
D O I
10.1016/j.vaccine.2011.04.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The endpoint definition for infant tuberculosis (TB) vaccine trials should match the TB disease phenotype expected in the control arm of the study population. Our aim was to analyse selected combinations of the clinical, radiological, and microbiological features of pulmonary TB among children investigated under vaccine trial conditions, in order to estimate case frequency for a range of expected TB phenotypes. Two thousand one hundred and eighty five South African children were investigated over a nine-year period (2001-2009). Evidence of TB exposure and classical symptoms were several times more common than chest radiography (CXR) compatible with TB, or positive Mycobacterium tuberculosis culture. Discordance between clinical, radiological, and microbiological features was common in individual children. Up to one third of children with compatible CXR, and up to half the children who were M. tuberculosis culture positive, were asymptomatic. The culture positive rate fell over time, although rates of TB exposure and compatible chest radiography increased. Consequently, the annual incidence of diagnostic combinations that included M. tuberculosis culture fell to <0.2%. However, in this study population (children <2 years of age), annual incidence of the TB disease phenotype that included the triad of TB exposure, symptoms, and compatible CXR, approached 1% (n = 848 per 100,000). These findings allow modelling of expected TB case frequency in multi-centre infant TB vaccine trials, based upon benchmarking of diagnostic data against the key indicator variables that constitute the building blocks of a trial endpoint. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4316 / 4321
页数:6
相关论文
共 9 条
  • [1] Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials
    Hatherill, Mark
    Verver, Suzanne
    Mahomed, Hassan
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (04) : 493 - 501
  • [2] Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers
    Kaufmann, Stefan H. E.
    Weiner, January, III
    Maertzdorf, Jeroen
    EXPERT REVIEW OF VACCINES, 2017, 16 (08) : 845 - 853
  • [3] Immunobiology of Pediatric Tuberculosis: Lessons Learned and Implications for an Improved TB-Vaccine
    Boer, Mardi C.
    Lewinsohn, Deborah A.
    Lancioni, Christina L.
    JOURNAL OF PEDIATRIC INFECTIOUS DISEASES, 2018, 13 (02) : 113 - 121
  • [4] Estimating the annual risk of infection with Mycobacterium tuberculosis among adolescents in Western Kenya in preparation for TB vaccine trials
    Videlis Nduba
    Anna H. van’t Hoog
    Annefleur de Bruijn
    Ellen M. H. Mitchell
    Kayla Laserson
    Martien Borgdorff
    BMC Infectious Diseases, 19
  • [5] "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report
    Boggiano, Cesar
    Eichelberg, Katrin
    Ramachandra, Lakshmi
    Shea, Jaqueline
    Ramakrishnan, Lalita
    Behar, Samuel
    Ernst, Joel D.
    Porcelli, Steven A.
    Maeurer, Markus
    Kornfeld, Hardy
    VACCINE, 2017, 35 (27) : 3433 - 3440
  • [6] Estimating the annual risk of infection with Mycobacterium tuberculosis among adolescents in Western Kenya in preparation for TB vaccine trials
    Nduba, Videlis
    van't Hoog, Anna H.
    de Bruijn, Annefleur
    Mitchell, Ellen M. H.
    Laserson, Kayla
    Borgdorff, Martien
    BMC INFECTIOUS DISEASES, 2019, 19 (01)
  • [7] Diagnostic Value of Interferon-gamma Release Assays (QuantiFERON-TB Gold® In Tube) in Childhood Tuberculosis
    Dayal, Rajeshwar
    Verma, Vikas
    Sharma, B.
    Kumar, G.
    Kumar, N.
    Gupta, R.
    Katoch, V. M.
    Joshi, Beenu
    Chauhan, D. S.
    INDIAN JOURNAL OF PEDIATRICS, 2012, 79 (02) : 183 - 187
  • [8] Diagnostic Value of Interferon- gamma Release Assays (QuantiFERON-TB Gold® In Tube) in Childhood Tuberculosis
    Rajeshwar Dayal
    Vikas Verma
    B. Sharma
    G. Kumar
    N. Kumar
    R. Gupta
    V. M. Katoch
    Beenu Joshi
    D. S. Chauhan
    The Indian Journal of Pediatrics, 2012, 79 : 183 - 187
  • [9] Potential Cost-Effectiveness of a New Infant Tuberculosis Vaccine in South Africa - Implications for Clinical Trials: A Decision Analysis
    Ditkowsky, Jared B.
    Schwartzman, Kevin
    PLOS ONE, 2014, 9 (01):